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ABSTRACT OF THE DISSERTATION 
 
Non-communicable diseases (NCDs) among people living with HIV (PLWH) in Cambodia  
 
by  
 
Kennarey Seang  
Doctor of Philosophy in Epidemiology  
University of California, Los Angeles, 2020  
Professor Pamina M. Gorbach, Chair  
 
 
Objectives: Research from high-income countries (HICs) appeared to suggest that Human 
Immunodeficiency Virus (HIV) and antiretroviral therapy (ART) contribute to, alongside other 
well-established traditional risk factors, higher prevalence of non-communicable diseases 
(NCDs) such as diabetes and hypertension among people living with HIV (PLWH). Many of 
these chronic metabolic disorders are known to increase cardiovascular disease (CVD) risk, 
which can be assessed using available risk stratification models. However, in certain low- and 
middle-income countries (LMICs), such as Cambodia, the relationship between NCDs and CVD 
risk and HIV is generally under-studied. This is even more so for young people living with HIV 
(YLWH). Therefore, I examined the relationship between NCDs and HIV among Cambodian 
general population and PLWH including YLWH.  
Design: Cross-sectional studies. 
Methods: Chapter 2 and 3 used merged data from two surveys among PLWH (n=510) and the 
general population (n=2747), aged between 22-65+ years, conducted by KHANA Center for 
Population Health Research (nongovernmental organization) in 2015 and by the University of 
Health Sciences in 2016, respectively. Both employed a standardized questionnaire and 
 iii 
physical/biochemical measurement protocols developed by the World Health 
Organization (STEPwise Approach to Surveillance or STEP survey or STEPS). Chapter 4 
employed a STEP survey to gather information on 370 YLWH, aged 18-29 years, from three 
HIV clinics (known as Opportunistic Infections and Antiretroviral therapy or OI/ART clinics) in 
Phnom Penh. The information on the young general population was then obtained from the 2016 
STEP survey. For each study, we computed NCD prevalence, plus CVD risk score based on the 
Framingham Risk Score (FRS) equations (study 2). We performed logistic regression to examine 
the relationship between NCDs and CVD risk and HIV while adjusting for age, sex, residence 
location, behavioral risk factors (such as smoking, heavy alcohol consumption, less than 5 
servings of fruits and vegetables and low physical activity) and body mass index (BMI).  
Results: Chapter 2 showed that the prevalence of hypertension and high cholesterolemia among 
adult PLWH were lower than that of the general population. However, the prevalence of diabetes 
and prediabetes was higher among PLWH; the odds of prediabetes, aOR=7.30 (95% CI: 5.69, 
9.36), and of diabetes, aOR=1.46 (95% CI: 0.99, 2.17), were higher among PLWH than the 
general population. Next, chapter 3 showed that PLWH appeared to be as likely as the general 
population to have moderate-to-high (estimated) 10-year CVD risk, aOR=0.88 (95% CI: 0.60, 
1.29). Finally, among YLWH (chapter 4), the prevalence of diabetes and hypertension is 4% 
(n=16) and 6% (n=22), respectively, among YLWH, compared to 1% (n=4) and 4% (n=22), 
among the general population of the same age group. We observed higher odds of 
diabetes/prediabetes among YLWH compared with the young general population, aOR=6.64 
(95% CI: 3.62, 12.19). Additionally, YLWH were at much higher odds of high cholesterolemia, 
aOR=7.95 (95% CI: 3.98, 15.87), than the young general population.  
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Conclusion: To combat a future burden of NCDs and potentially their related morbidity and 
mortality, our studies underlined the need to set up essential intervention strategies, be it 
behavioral modification or medical intervention, in order to properly address these conditions 
among population living with HIV including YLWH. In addition to interventions, monitoring 
and screening efforts should also be put in place among this population given their susceptibility 
to develop these conditions at a younger age than the general population.  
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Chapter 1. Introduction and background  
 
In low- and middle-income countries (LMICs), the transition from infectious diseases to 
non-communicable diseases (NCDs) burdens the health system and calls for effective integration 
of their care and management (1, 2). In addition, at the present time, many infections (due to 
advance in treatments) are becoming chronic conditions themselves; and there is no better 
example than in the case of infection with Human Immunodeficiency Virus (HIV) (2-8). 
Advances made in the HIV treatments helped people living with HIV (PLWH) survive into older 
age, therefore, rendering them susceptible to chronic diseases and age-related co-morbidities, as 
the general population (5, 9-13). Findings from high-income countries (HICs) also suggested that 
PLWH might be at even higher risk of developing these NCDs than those uninfected due to the 
HIV infection as well as the antiretroviral therapy (ART) (1, 3, 5-7, 9, 14-20). 
However, many LMICs lack epidemiological research on these chronic diseases among 
PLWH and the complex interaction between HIV-specific factors and NCD traditional risk 
factors (1, 9, 16, 18, 21, 22). As a result, an assessment of NCD prevalence as well as their risk 
factors among population that differs by their HIV status is still limited (1, 9). This is also the 
case for Cambodia. This assessment can help us understand the extent to which the HIV 
infection and ART contributed to increased risk of NCDs among PLWH and identify those who 
might be at higher risk of these conditions so that appropriate interventions can be proposed to 
them in a timely manner.  
Without measures taken to properly address these NCDs among PLWH, the efforts put 
forth in terms of universal ART coverage will end up being wasted (1, 18, 22).   
1.1. Epidemiological research on NCDs among PLWH in Cambodia  
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In 10 years, researchers estimated that deaths from NCDs will surpass those from 
infectious diseases as their prevalence continue to rise across the globe (10). In Cambodia, 
according to the World Health Organization (WHO), 64% of total deaths are from NCDs (23). A 
few years ago, Cambodian researchers, health professionals alike, started making headlines on 
these so-called slow “silent killers” (24). However, research publications addressing NCDs were 
still then very limited in the country, representing only about 8% of total publications over the 
period of more than a decade from 2000 to 2012 (24). In 2010, the Cambodia’s Ministry of 
Health (MOH), in collaboration with the WHO as well as other local and international partnering 
institutions, launched the first STEPwise Approach to Noncommunicable Disease Risk Factor 
Surveillance, or in shorts, STEPS or STEP survey, as part of the attempt to describe the burden 
of NCDs and their risk factors among the Cambodian general population (25, 26). Five years 
later (2015), the first STEPS survey among PLWH was conducted in Cambodia by KHANA 
Population Center for Health Research (14, 19). Afterward (in 2016), the STEPS survey among 
the general population in Cambodia was conducted for the second time by the University of 
Health Sciences.  
It should be noted that each survey described the prevalence of chronic conditions such as 
diabetes, hypertension and high blood cholesterol, along with their behavioral risk factors, 
among different study populations. KHANA Population Center for Health Research did a STEP 
survey among PLWH only, while the 2010 and 2016 STEP surveys were conducted among the 
general population. Although at a glance, the prevalence of NCDs differs among the two 
populations, there was no epidemiological study that compares PLWH and the general 
population in Cambodia.  
1.2. Cardiovascular disease (CVD) and their risk assessment among PLWH 
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NCDs are not created equal. Cardiovascular disease (CVD) accounts for the most deaths 
each year globally (27) and is the major cause of death among PLWH (28, 29). According to Dr 
Galea Gauden, the WHO’s representative for the People’s Republic of China, “The probability 
of dying between ages 30 and 70 years from the four main NCDs is 18%” (30). In Cambodia, 
deaths from CVD accounted for 24% of total deaths from NCDs (23).  
In the context of HIV, in addition to known behavioral risk factors, HIV-specific factors 
have been linked with increased risk of CVD either independently or by means of increasing 
CVD metabolic risk factors (28, 31-37). However, regardless of HIV status, according to the 
WHO, by eliminating certain behavioral risk factors, we could potentially and significantly 
reduce both the burden and mortality of CVD (27). This denotes the importance of CVD risk 
stratification or risk prediction among vulnerable and at risk population in order to identify those 
who are in need of interventions (34, 38-41). Because CVD risk estimation models takes into 
account each individual risk profile, it is recommended to be performed regularly after a certain 
age, depending on the model used (38, 42).  
There are several risk prediction models but only one was specifically developed for 
PLWH, i.e. one that incorporates some HIV-specific factors in their equations (28, 42, 43). 
However, CVD risk prediction model for PLWH (named the D:A:D model) had not been widely 
validated and its predictive ability remains somewhat questionable (43-45). Therefore, experts 
recommend using models which had been developed for the general population such as 
Framingham Risk Score (FRS) or Atherosclerotic Cardiovascular Disease (ASCVD) score to 
assess CVD risk among PLWH (43, 45). This recommendation is based on the fact that 
traditional risk factors (smoking, alcohol consumption and lack of physical activity, for instance) 
still play significant roles in CVD development, even among those living with HIV (37). 
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1.3. Young population and NCD risk factors  
 
Despite their young age, young people (adolescents and young adults) are actually prone 
to adopting many unhealthy lifestyle behaviors, such as smoking and substance abuse, some of 
which might be contributing to the development of chronic diseases in their late adulthood (46-
49). Evidence suggests that these risk behaviors, the majority of which, are associated with 
overweight/obesity and NCDs, are becoming increasingly common among youth (49). Lack of 
measures to address and prevent these behaviors among young population now will only 
exacerbate the problems faced by both the future populations and health care system. In the 
United States, besides having high prevalence of NCD risk factors, young people aged 16-24 
years, were heavily affected by HIV (50). Unfortunately, Cambodia has no official report on this 
specific young population, neither their HIV nor NCD prevalence rates.  
Young people add value to NCD research and have the capacity to shape the future 
course of NCD epidemic by becoming parts of the prevention strategies (49). This is particularly 
important at the present time, when many LMICs are or will be going through demographic 
transition, and urbanization as well as migration patterns are fast becoming a global trend (15, 
51). In addition, mounting evidence suggested that rising income levels in LMICs could 
potentially lead to an increase in the prevalence of NCD risk factors, such as overweight and 
obesity in the future (51). We can, therefore, reasonably expect to see a rise in prevalence rate of 
NCDs now or in the near future among our young people including, of course, those living with 
HIV.  
In Cambodia, often times, past studies usually focused on sexual risk behaviors other 
than those related with NCDs, or they targeted specific groups such as young sex workers or men 
who have sex with men (MSM) other than young people living with HIV (YLWH) in general 
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(52-59). Therefore, young population or YLWH in general remain largely understudied and their 
health needs as well as their risk profile were largely under-addressed.  
The health of the future populations depends on that of today’s populations, the 
importance of NCD research among young people could not be overstated.  
Thus, in order to halt the future NCD morbidity and mortality in Cambodia, we need to 
start focusing on young people and their behaviors which carry risk for present or future 
(chronic) disease development (46). Unlike the young general population, in the context of HIV, 
YLWH can easily benefit from their regular engagement in care in terms of simple screening or 
treatment procedures. These simple measures might have a huge impact on their late adult health. 
Similar to the general population, their risk of chronic diseases could as well be prevented, 
mainly, through proper and timely course of preventive measures. 
Each of the studies I proposed tackled different population subsets in terms of their NCD 
burden and risk. Both assessments of disease burden and risk contribute to scientific knowledge 
from LMICs and help inform the future course of public health research priorities and potential 
resource allocation. 
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Chapter 2. Study 1: Differences in prevalence and risk factors of non-
communicable diseases (NCDs) between people living with HIV (PLWH) and 
the general population in Cambodia  
 
2.1. Abstract  
 
Objectives: Human Immunodeficiency Virus (HIV) and antiretroviral therapy (ART) had been 
associated with increased risk of non-communicable diseases (NCDs) such as diabetes and 
hypertension alongside other well-established traditional risk factors. Empirical evidence from 
low- and middle-income countries (LMICs) on this relationship are scarce. Therefore, we 
examined the prevalence of NCDs in people living with HIV (PLWH) and the general population 
in Cambodia to assess the contribution of HIV and ART on NCDs and identify if locally adapted 
policies and/or interventions are needed.  
Design: Cross-sectional survey.  
Methods: We merged data from two surveys conducted among PLWH (n=510) and the general 
population (n=2747), aged 22 and up, by KHANA Center for Population Health Research 
(nongovernmental organization) in 2015 and by the University of Health Sciences in 2016, 
respectively. Both employed a standardized questionnaire and physical/biochemical 
measurement protocols developed by the World Health Organization (STEPwise Approach to 
Surveillance or STEP survey or STEPS) and were conducted across selected provinces in 
Cambodia. We computed NCD prevalence and performed logistic regression to examine the 
relationship between NCDs and HIV while adjusting for age, sex, residence location, behavioral 
risk factors (smoking, heavy alcohol consumption, less than 5 servings of fruits and vegetables 
and low physical activity) and body mass index (BMI). 
Results: The prevalence was 9% (n=46) for diabetes, 13% (n=67) for hypertension and 3% 
(n=16) for high cholesterolemia among PLWH, all of which (except diabetes) were lower than 
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that of the general population. PLWH were more likely to present prediabetes, aOR=7.30 (95% 
CI: 5.69, 9.36) and diabetes, aOR=1.46 (95% CI: 0.99, 2.17), and less likely to present 
hypertension and high cholesterolemia, aOR=0.58 (95% CI: 0.42, 0.80) and aOR=0.13 (95% CI: 
0.08, 0.23), respectively.  
Conclusion: High prevalence of prediabetes and diabetes among PLWH underscores the need to 
put in place proper treatment and screening measures to address these conditions among this 
population. 
2.2. Introduction  
 
The increase in the coverage of antiretroviral therapy (ART) is marked with an increase 
in life expectancies of people living with Human Immunodeficiency Virus or HIV (PLWH) and, 
to various extent, in other age-related co-morbidities and non-communicable diseases or NCDs 
(7, 14, 19, 60-62). The infection, the virus and the treatments might act independently and/or by 
influencing known traditional risk factors for NCDs (33, 63). As a result, NCD risk might be 
higher among PLWH and this had been reported in many studies conducted in HICs (11, 12, 64, 
65). Their increased NCD risk could be due to prolonged ART use and certain ART regimen (45, 
66-68), but it also depends on whether or not they present with other known traditional risk 
factors of these NCDs, as in the case of the general population (69). 
However, country-specific epidemiological data is still lacking in many low-middle-
income countries (LMICs) (16, 18, 21). This data is important because differences in the 
distribution of NCD traditional and HIV-specific risk factors across country settings raised 
concerns on whether findings from HICs could also be applicable to other settings (5, 16, 18, 21, 
65).  
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Cambodia is home to roughly 16 million people (70). Approximately 65,000 were 
estimated to be living with HIV and the ART coverage was about 80% as of 2016 estimate (71). 
The country underwent a demographic and epidemiological transition since 2000 as NCD 
mortality overtook that of infectious diseases (24). Despite this, the transition of public health 
research focus from infections to NCDs has been slow, resulting in very few research studies 
addressing NCDs over the years (24).  
Therefore, we examined the relationship of these NCDs and HIV by comparing the 
prevalence of NCDs among the general population with that of PLWH in Cambodia. Our study 
will help identify whether PLWH in Cambodia are at increased risk of certain conditions that 
merit early or regular screening as well as other types of interventions.  
2.3. Methods 
 
Information on the general population and those who are living with HIV was obtained 
by merging STEP1 surveys conducted by the University of Health Sciences (UHS) in 2016 and 
by KHANA Center for Population Health Research in 2015, respectively. Both surveys had > 
90% response rates and included information on socio-demographics, behavioral risk factors, 
and measurements of blood pressure, total cholesterol, and glucose levels. Blood pressure was 
measured three times, five minutes apart, and the average was used for high blood pressure 
classification. Both glucose and cholesterol levels were measured in the morning before 
breakfast and after fasting the night before. Physical activity (recreation- or work-related) 
included locally-adapted activities, such as farming and household chores. Body Mass Index 
(BMI) classification was based on Asian-specific cutoffs.  
 
 
1 The World Health Organization (WHO) ‘s standardized questionnaire and measurement protocols called the 
STEPwise approach to NCD risk factor surveillance - STEP survey or STEPS. 
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We used a subset of the UHS’s survey pertaining only participants aged 22 and above 
(n=2747) to match that of KHANA’s study population (n=510). The details of the KHANA’s 
STEP survey were described elsewhere (14). It should be noted that, while KHANA conducted 
their survey at designated HIV clinics across 4 provinces and the capital city, UHS was a 
national household survey. The data collectors for both surveys were a mixture of medical 
(mostly nurses) and non-medical personnel; they all had undergone appropriate training with 
human subjects certified trainers of their corresponding institutions.  
Definition and classification (72-76) 
Definition and classification of variables are as follow: 1) smokers refer current (daily or 
not) users of any tobacco products. 2) heavy drinkers refer to those who had, during the past 
week: 4 standard drinks2 or more on any one occasion or 14 standard drinks or more in total 
(men), or 3 standard drinks or more on any one occasion or 7 standard drinks or more in total 
(women). 3) fruit and vegetable consumption refer to any one-day consumption on a typical 
week within the past year. 4) low physical activity refers to less than 75 minutes of work or 
recreation activity of vigorous intensity per week or less than 150 minutes of recreation activity 
of moderate intensity per week. 5) nutritional status – underweight refers to BMI < 18.5, normal 
weight refers to BMI between 18.5 and 23, overweight and obese refers to BMI ≥ 23 and BMI ≥ 
25, respectively. 6) Hypertension: mean systolic blood pressure (SBP) ≥ 140 mmHg and/or mean 
diastolic blood pressure ≥ 90 mmHg (DBP) and/or on anti-hypertensive drugs. 7) Diabetes: 
fasting glucose ≥ 126 mg/dL and/or on anti-diabetic drugs. 8) Prediabetes: fasting glucose 
between 101-125 mg/dL. 9) Prehypertension: mean SBP between 120-139 mmHg and/or mean 
 
 
2 A standard drink is defined as one with a net content of approximately 10g of pure ethanol (in accordance with the 
WHO’s STEP survey showcards’ contents).  
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DBP between 80-89 mmHg. 10) High cholesterolemia: total cholesterol between ≥ 240 mg/dL 
and/or on cholesterol lowering drugs. 11) Borderline- high cholesterolemia: total cholesterol 
between 200-239 mg/dL.  
Power calculation and statistical analysis 
The present study (N=3257) has more than 90% power to detect differences in the 
prevalence of prediabetes, hypertension, high and borderline-high cholesterolemia.  
We calculated the prevalence of hypertension, prehypertension, diabetes, prediabetes, 
high and borderline-high cholesterolemia among PLWH and the general population. We fitted a 
separate logistic regression model to examine the association between each of these conditions 
and HIV, reporting the crude and adjusted odds ratios (ORs), controlling for confounders 
including age, sex, residence location (Phnom Penh vs. provinces), behavioral risk factors 
(smoking, heavy drinking, less than 5 servings of fruits and vegetables, low physical activity) 
and BMI. All analyses were performed using STATA 14 (Copyright 1985-2015 StataCorp LLC).  
Ethical considerations 
The current study was approved by the Institutional Review Board of the University of 
California Los Angeles (UCLA IRB#18-001789) in 2018 and the National Ethics Committee for 
Health Research in Cambodia (NECHR #010) in 2019. All study volunteers provided verbal and 
written consents and understood that no identifying information or blood sample had been 
collected or stored.  
2.4. Results  
 
Socio-demographics  
Findings on socio-demographic and other characteristics are described in details in Table 
2-1. We had a total of 3257 study volunteers, aged between 22-78 years. The only similarities 
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between the two groups were in terms of their mean age and gender distribution. The mean age 
was around 44 years (SD=8) and 45 years (SD=13) for the general population group and PLWH, 
respectively. Female participants accounted for about two-thirds in each group.  
Other characteristics (education, occupation and marital status) were quite distinct (likely 
related to differences in their residence location). PLWH were more likely than the general 
population to have had at least primary education (49% (n=249) vs. 21% (n=577)), but the 
percentage of those who reported having completed high school or higher were comparable 
among these two groups (approximately 5%). The majority of participants from both groups 
were either salary- or self-employed (which includes farmers). These two employment statuses 
accounted for 75% (n=385) of PLWH and 85% (n=2333) of the general population. Over two-
thirds of participants from both groups were from provinces, although this was much more 
significant among the general population, 95% (n=2607), than PLWH, 74% (n=378).  
Prevalence of behavioral risk factors and NCDs 
Heavy alcohol consumption was more common among the general population, 22% 
(n=212), than PLWH, 8% (n=18), while smoking was similar between the two groups (15% or 
n=75 for PLWH and n=429 for the general population). Low physical activity, on the other hand, 
was more prevalent among PLWH, 31% (n=98), than the general population, 17% (n=222). 
Overweight and obesity was higher in the general population group (41% (n=1102) vs. 22% 
(n=113) in PLWH).  
Half of PLWH (n=255) had prediabetes compared with only 16% (n=374) of the general 
population, while diabetes differed only slightly among them (Table 2.1). Although high 
cholesterolemia was rather prevalent among the general population (20% (n=517)), its 
prevalence was only 3% (n=16) among PLWH. Similarly, hypertension was 22% (n=600) and 
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13% (n=67) among the general population and PLWH, respectively. More details on these 
conditions, their risk factors and other socio-demographics are in Table 2-1.  
We also noted higher percentage of smoking and heavy alcohol use among male than 
female participants, although more female participants had low physical activity and high BMI 
(Figure 2-1).  
HIV-specific factors and NCDs  
We presented in Table 2.2 the distribution of some HIV-specific factors by NCD status. 
The majority of our PLWH had been behaviorally infected and the average duration of HIV 
duration was about 10 years. There appeared to be no association between any of the HIV-
specific factors and NCDs, except for hypertension and prehypertension (with high CD4 cell 
count measured within the last 6 months), and for high and borderline-high cholesterolemia (with 
being behaviorally infected and duration of HIV infection) (Table 2.2).  
Associations between NCDs and HIV 
We reported in Table 2-3 the results from logistic regression models that examined the 
effect of HIV on glucose status. We found that PLWH appeared to be at higher odds of 
prediabetes, aOR=7.30 (95% CI: 5.69, 9.36) and, to a lesser extent, diabetes, aOR=1.46 (95% CI: 
0.99, 2.17). Additionally, we showed the relationship between fasting glucose levels and HIV 
status, stratified by BMI (Figures 2-2) and by sex (Figure 2-3). PLWH always had higher 
fasting glucose levels regardless of their BMI status and sex.  
On the contrary, PLWH were much less likely than the general population to present 
hypertension, aOR=0.58 (95%CI: 0.42, 0.80) (Table 2-4), and high cholesterolemia, with 
aOR=0.13 (95% CI: 0.08, 0.23) (Table 2-5). Similarly, we observed lower odds of 
prehypertension (Table 2-4) and borderline-high cholesterolemia (Table 2-5) among PLWH.  
 13 
2.5. Discussion  
 
We found higher prevalence of prediabetes and diabetes and lower prevalence of 
hypertension and high cholesterolemia among PLWH, compared with the general population. 
Although the roles of HIV infection and ART had been implicated in the pathophysiological 
pathways of certain metabolic disorders among PLWH (33, 77), findings across different studies 
had been inconsistent.  
Diabetes and prediabetes  
A diabetes incidence rate of 10% among HIV-infected individuals (compared with 3% 
among those uninfected) had been reported by the Multicenter Aids Cohort Study (MACS) over 
4 years of follow-up (78). A 6-year incidence rate of 7% was reported from a study based on data 
from the TREAT Asia HIV Observational Database (TAHOD), but much lower rates had been 
reported in other cohorts including the Swiss HIV Cohort, and the D:A:D study (66). Similarly, 
A systematic review and meta-analysis of over 40 articles on glucose metabolism status among 
PLWH reported overall cumulative incidence of approximately 5% (values range from 3-13%) 
for diabetes and 15% for prediabetes (values range from 0-50%) (79). However, of all these 
reported numbers excluded prevalent cases, which might partially explain why most of their rates 
were slightly lower compared to ours.  
Based on the data from 3 large HIV clinics in London, the prevalence was 15% and 17% 
for diabetes and prediabetes, respectively; and PLWH appeared to be at higher risk of diabetes 
(2-fold) compared with the general population (80, 81). Higher diabetes prevalence in their study 
could have been due to the different age and demographic constitution of their study population 
compared to ours: their median age was older (49 years), their clients were mostly Caucasian, 
followed by Black African and Black Caribbean, and more than 70% were male (80, 81). On the 
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contrary, HIV did not appear to increase diabetes risk in the Danish cohort, but this cohort was 
predominantly white and younger than ours as well (81, 82). 
Nevertheless, our diabetes prevalence was comparable with a study that utilized National 
Health Nutrition Examination Survey (NHANES) and Medical Monitoring Project (MMP) and 
another study in Iran (83, 84). The first one reported the prevalence of diabetes at 8% and 10% in 
the general population and in PLWH, respectively (83). The second study (Iran) found that 6% 
and 50% of their study population had diabetes and prediabetes, respectively (84). There were 
also other studies that reported a high prevalence of prediabetes (> 30% ) among PLWH (78, 85), 
affirming that prediabetes can be very common among this population, as demonstrated in our 
findings. Additionally, similar to our results shown in Table 2-1, one Chinese study reported 
higher mean glucose levels in PLWH than those uninfected, but their sample consisted of only 
men (85).  
To sum up, these seemingly quite different figures reported from various studies could be 
the result of many factors. First, it has been established that along with BMI, age, sex and 
race/ethnicity, HIV infection and ART regimen also have influences on glucose (Nucleoside 
Reverse Transcriptase Inhibitors “NRTIs” in particular) and lipid metabolism (66, 79, 81, 86), 
therefore, fluctuations in the prevalence or incidence rates across these different studies could 
very well be the reflection of differences in the distribution of traditional risk factors and HIV-
specific factors among the study populations. In our sample of PLWH, 78% were on 
combination therapy (NRTTs and Non-Nucleoside Reverse Transcriptase Inhibitors “NNRTIs”) 
and 42% of them were on Zidovudine (result not shown). Zidovudine is a type of NRTIs that has 
been linked with significant risk of diabetes (86, 87).  
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Second, the reporting of incidence or prevalence rates also made it challenging to directly 
compare across studies.    
Lastly, the definitions of diabetes and prediabetes used were not always consistent across 
studies. Although, the majority of studies would use a standard definition of fasting glucose 
above 126 mg/dL to determine the diabetes status and/or self-report diabetes status (78), others 
might use glycate hemoglobin (HbA1C), the oral glucose tolerance test with or without self-
reported diabetes status (66, 80, 83). Discrepancies in each test’s sensitivity and specificity 
functions could potentially result in discrepancies in these reported figures.  
Hypertension and high cholesterolemia  
Our findings on hypertension was comparable to the Polish study which reported higher 
incidence rate of hypertension among the general population (33%) than PLWH (28%) (88), and 
to some other cross-sectional studies conducted in China and India (85, 89). In addition, lower 
mean systolic and diastolic blood pressure as well as lower hypertension prevalence among 
PLWH (compared with those uninfected) had also been published in a 2015 review article (69). 
However, other meta-analyses reported a higher prevalence of hypertension among PLWH 
compared with those uninfected (68, 90). Although we should note that both of these meta-
analyses included significantly more studies from HICs than LMICs and it was not clear if each 
study included in the analyses classified those on anti-hypertensive medications as hypertensive 
as we did in our study.  
Our findings on total cholesterolemia were similar to some other Asian observational 
studies reported in a 2017 systematic review on cardiovascular disease risk (85). Mean total 
cholesterolemia had been found to be lower in PLWH compared to those uninfected in two 
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cross-sectional studies, one conducted in South Korea and another one in China (85, 91), and in 
one case-control study in China (85).  
Lower prevalence of hypertension and high cholesterolemia among PLWH in our study 
could be due to multiple reasons. First, we showed that traditional risk factors for hypertension 
and high total cholesterol, such as smoking, heavy drinking and overweight/obesity, were less 
common among our PLWH participants, who, due possibly to their regular interaction with 
health care workers, were probably more health conscious. Second, the ART usually linked with 
dyslipidemia is PIs (37, 45), a regimen that is taken by only 3% of PLWH in our sample. Third, 
low prevalence of hypertension among PLWH might also explain a low prevalence of high blood 
cholesterol because the latter had been known to also increase risk of hypertension (67). The 
general population had higher prevalence of cholesterolemia, as a result, they also had higher 
prevalence of hypertension. Lastly, our general population group came from a household STEP 
survey, it might have been the case that the survey selectively captured a lot more population 
who were not healthy and, therefore, more likely to be home.   
Limitations  
 
We also reckon several limitations of our study. First, we took careful interpretations 
derived from any associations between HIV and NCDs, suggested by these survey data. We have 
no means of knowing for sure if these conditions actually occurred after HIV infection for our 
participants who are living with HIV. Nevertheless, on average, PLWH in our study sample had 
been living with the infection for almost 10 years, and given their average age (around 44 years), 
it is highly unlikely that our PLWH had had these conditions before the onset of HIV infection, 
as the prevalence of chronic diseases among younger population in Cambodia was quite low in 
the past (based on the 2010 STEPS report) (26).  
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Second, because we were not able to ascertain the HIV status for our participants in the 
general population, misclassification might have occurred. However, the prevalence of HIV 
among the general population is less than 1% in Cambodia, the amount of misclassification, if 
there is any, seems to be too small to alter any associations we observed.  
Lastly, there were several covariates related to the NCDs that were not measured in the 
original surveys, which includes oral contraceptive use (for women) and birth history 
(prematurity or low birth weight). As a result, we could not account for any of these factors in 
the analysis. Nevertheless, the focus of the STEP survey is the modifiable lifestyle factors, many 
of which were included in our regression model.  
Conclusion 
High prevalence of prediabetes and diabetes among PLWH in Cambodia compared with 
the general population raises questions and concerns over early and regular screening measures 
and future management for the HIV-diabetes co-existence. In addition, the Cambodia’s HIV 
treatment guidelines might need to be further investigated as 70% of children living with HIV 
under the age of 15 had Zidovudine in their ART regimen3, a type of NRTI known to increase 
diabetes risk. Future studies should examine why there were significant differences in the 
distribution of some HIV-specific factors among those with certain NCDs (high blood pressure 
and elevated total cholesterol) but not others (diabetes and prediabetes).  
Regardless of HIV status, many of these conditions could be lessened to a great extent 
with timely lifestyle interventions as well as easily available medications. Without proper 
treatment or screening measures to address prediabetes, diabetes is inevitable. Moreover, without 
 
 
3 Annual Report 2016. MOH/NCHADS. Cambodia. 2016.  
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reinforcing screening recommendations and lifestyle education among this vulnerable 
population, the future burden of these conditions and other NCDs, such as cardiovascular disease 
will have huge economical and logistical effects on our resource-restrained health care system.  
2.6. Tables and figures  
Table 2-1. Key characteristics of study participants, STEPS, Cambodia, 2015/2016. 
Characteristics  
PLWH 
(n=510) 
General 
population 
(n=2747) 
Socio-demographics n % n % 
Gender      
 Male  170 33.3 884 32.2 
 Female  340 66.7 1863 67.8 
Age (mean, SD) (44.8, 12.7) (44.3, 8.4) 
 22-34  43 8.4 742 27.0 
 35-44  212 41.6 663 24.1 
 45-55  191 37.5 643 23.4 
 55+  63 12.4 699 25.5 
Education       
 None or less than primary 115 22.6 1713 62.4 
 Completed primary 249 48.8 577 21.0 
 Completed secondary 121 23.7 312 11.4 
 Completed high school or higher 25 4.9 144 5.2 
Occupation       
 Salary employed  155 30.4 257 9.4 
 Self-employed 230 45.1 2076 75.6 
 Unemployed  125 24.5 414 15.1 
Marital status       
 Single  8 1.6 130 4.7 
 Married+cohabiting 314 61.7 2175 79.2 
 Separated   6 1.2 62 2.3 
 Divorced   39 7.7 62 2.3 
 Widowed   142 27.9 318 11.6 
Residence location     
 Province  378 74.1 2607 94.9 
 Phnom Penh  132 25.9 140 5.1 
NCD risk factors       
Smokers   75 14.7 429 15.6 
Heavy drinkers   18 8.5 212 22.3 
< 5 servings of fruits and vegetables  466 91.5 1446 53.0 
Low physical activity  98 30.9 222 17.0 
Body Mass Index (BMI)     
 Normal weight  297 58.3 1217 45.5 
 Underweight  99 19.5 355 13.3 
 Overweight and obese  113 22.2 1102 41.2 
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Table 2-1. Key characteristics of study participants, STEPS, Cambodia, 2015/2016. (continued) 
 
Characteristics PLWH 
(n=510) 
General 
population 
(n=2747) 
NCDs  n % n % 
Blood glucose      
 Prediabetes  255 55.2 374 16.1 
 Diabetes  46 9.1 185 7.4 
 Fasting blood glucose† (mean, SD) (106.3, 24.0) (94.0, 31.3) 
Blood pressure       
 Prehypertension 148 33.5 810 38.0 
 Hypertension   67 13.2 600 22.0 
 SBP† (mean, SD) (117.9, 16.2) (119.7, 18.1) 
 DBP† (mean, SD) (73.8, 10.2) (78.6, 11.7) 
Total cholesterol      
 Borderline-high  93 18.9 671 32.3 
 High  16 3.2 517 19.9 
 Fasting total cholesterol† (mean, SD) (180.3, 30.7) (198.8, 50.6) 
Currently on treatment     
High blood pressure  22 4.3 172 6.3 
Diabetes   1 0.2 59 2.2 
High total cholesterol 2 0.4 18 0.7 
 SD, Standard Deviation.  
 † Excluded those currently on treatment for each specified condition.  
Table 2-2. Distribution of HIV-specific factors by NCD status, STEPS, Cambodia, 2015/2016. 
HIV-specific factors  
Diabetes and 
prediabetes  
Hypertension 
and 
prehypertension 
High and 
borderline-high 
cholesterolemia 
   n (%) n (%) n (%) 
On ART 24 months or longer 281 (95.3) 201 (96.6) 104 (98.1) 
> 350 CD4 cell count 178 (69.0) 111 (61.3)* 67 (72.0) 
NRTI and NNRTI (vs. regimen with PI) 271 (96.8) 196 (97.0) 96 (96.0) 
Behaviorally infected (vs. perinatally) 299 (99.3) 212 (98.6) 106 (97.3)* 
Living with HIV ≥ 60 months  259 (86.1) 186 (86.5) 100 (91.7) 
Duration of HIV infection (mean, SD) 9.8 (4.7) 9.6 (4.6) 10.7 (4.9)* 
NRTI, Nucleoside Reverse Transcriptase Inhibitor.  
NNRTI, Non-Nucleoside Reverse Transcriptase Inhibitor. 
PI, Protease Inhibitor. 
* P-value ≤ 0.05. 
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Table 2-3. Association between diabetes and prediabetes and HIV, STEPS, Cambodia, 2015/2016. 
 
        Diabetes 
  
Prediabetes 
Predictors 
Crude OR 
(95% CI) 
Adjusted OR† 
(95% CI) 
Crude OR 
(95% CI) 
Adjusted OR† 
(95% CI)  
HIV+ (ref. general population) 1.30 (0.93, 1.82) 1.46 (0.99, 2.17)   6.73 (5.44, 8.34) 7.30 (5.69, 9.36)  
Female (ref. male) 1.05 (0.79, 1.40) 1.01 (0.74, 1.39)   0.91 (0.76, 1.10) 0.94 (0.76, 1.17)  
Age (ref. 22-34)            
  35-44  2.47 (1.30, 4.69) 2.32 (1.16, 4.64)   2.73 (2.04, 3.64) 1.59 (1.16, 2.17)  
  45-54  5.98 (3.30, 10.86) 5.83 (3.05, 11.12)   3.39 (2.53, 4.52) 2.13 (1.56, 2.89)  
  55+ 8.91 (4.95, 16.01) 9.57 (5.07, 18.06)   2.86 (2.12, 3.87) 2.64 (1.93, 3.61)  
Currently living in Phnom Penh  2.49 (1.72, 3.61) 1.88 (1.24, 2.83)   2.51 (1.88, 3.35) 1.02 (0.73, 1.42)  
  (ref. in provinces)            
2 or more behavioral risk factors‡ 0.97 (0.68, 1.37) 0.89 (0.61, 1.31)   1.49 (1.20, 1.84) 1.04 (0.80, 1.34)  
BMI (ref. normal weight)            
  Underweight  0.67 (0.39, 1.16) 0.56 (0.32, 0.98)   0.98 (0.75, 1.28) 0.87 (0.65, 1.17)  
  Overweight and obese  2.39 (1.79, 3.20) 2.33 (1.72, 3.16)   1.24 (1.04, 1.50) 1.69 (1.36, 2.10)  
CI, Confidence interval.  
Diabetes: fasting glucose ≥ 126 mg/dL and/or on anti-diabetic drugs.  
Prediabetes: fasting glucose between 101-125 mg/dL. 
† Adjusted for sex, age, residence location, behavioral risk factors and BMI.  
‡ Behavioral risk factors include smoking, heavy alcohol consumption, less than 5 servings of fruit and vegetable  
consumption and low physical activity. 
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Table 2-4. Association between hypertension and prehypertension and HIV, STEPS, Cambodia, 2015/2016. 
 
Predictors 
Hypertension    Prehypertension 
Crude OR 
(95% CI) 
Adjusted OR† 
(95% CI) 
  Crude OR  
(95% CI) 
Adjusted OR† 
(95% CI)   
HIV+ (ref. general population) 0.54 (0.41, 0.71) 0.58 (0.42, 0.80)   0.82 (0.66, 1.02) 0.77 (0.58, 1.00) 
Blood glucose (ref. normal)           
  Prediabetes 1.44 (1.16,1.79) 1.30 (1.02, 1.67)   1.37 (1.12, 1.68) 1.26 (1.00, 1.58) 
 Diabetes 3.83 (2.89, 5.08) 2.16 (1.58, 2.96)   1.87 (1.31, 2.68) 1.37 (0.93, 2.02) 
Blood cholesterol (ref. normal)           
  Borderline-high  1.56 (1.26, 1.92) 1.19 (0.95, 1.50)   1.20 (0.99, 1.47) 1.06 (0.85, 1.31) 
  High  2.62 (2.11, 3.27) 1.50 (1.16, 1.94)   1.90 (1.51, 2.40) 1.67 (1.28, 2.19) 
Female (ref. male) 0.79 (0.66, 0.95) 0.75 (0.60, 0.93)   0.64 (0.54, 0.76) 0.65 (0.53, 0.79) 
Age (ref. 22-34)           
  35-44      2.37 (1.70, 3.29) 2.27 (1.58, 3.25)   1.80 (1.44, 2.26) 1.75 (1.36, 2.25) 
  45-54      4.41 (3.21, 6.05) 4.03 (2.84, 5.72)   2.20 (1.75, 2.77) 2.09 (1.61, 2.70) 
  55+ 7.33 (5.36, 10.01) 6.04 (4.26, 8.57)   2.46 (1.93, 3.14) 2.35 (1.78, 3.09) 
Currently living in Phnom Penh  1.22 (0.91, 1.64) 1.01 (0.71, 1.44)   1.15 (0.86, 1.54) 0.98 (0.70, 1.37) 
  (ref. in provinces)           
2 or more behavioral risk factors‡ 1.26 (1.02, 1.56) 1.25 (0.97, 1.60)   1.34 (1.09,1.64) 1.19 (0.94, 1.52) 
BMI (ref. normal weight)           
  Underweight  0.70 (0.51, 0.98) 0.65 (0.46, 0.92)   0.64 (0.50, 0.83) 0.64 (0.48, 0.83) 
  Overweight and obese  2.74 (2.28, 3.30) 2.45 (2.00, 3.02)   1.85 (1.54, 2.21) 1.80 (1.48, 2.19) 
 CI, Confidence Interval.  
Hypertension: mean SBP ≥ 140 mmHg and/or mean DBP ≥ 90 mmHg and/or on anti-hypertensive drugs. 
Prehypertension: mean SBP between 120-139 mmHg and/or mean DBP between 80-89 mmHg.  
† Adjusted for diabetes status, blood cholesterol status, sex, age, residence location, behavioral risk factors and BMI. 
‡ Behavioral risk factors include smoking, heavy alcohol consumption, less than 5 servings of fruit and vegetable consumption and  
low physical activity. 
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Table 2-5. Association between high and borderline-high cholesterolemia and HIV, STEPS, Cambodia, 2015/2016. 
Predictors 
High cholesterolemia   Borderline-high cholesterolemia 
Crude OR 
(95% CI) 
Adjusted OR† 
(95% CI) 
  Crude OR 
(95% CI) 
Adjusted OR† 
(95% CI)   
HIV+ (ref. general population) 0.13 (0.08, 0.22) 0.13 (0.08, 0.23)   0.49 (0.38, 0.62) 0.46 (0.35, 0.61) 
Female (ref. male) 2.46 (1.94, 3.11) 2.41 (1.86, 3.13)   1.54 (1.28, 1.85) 1.57 (1.28, 1.92) 
Age (ref. 22-34)           
  35-44      0.96 (0.70, 1.33) 1.44 (1.00, 2.07)   1.09 (0.86, 1.39) 1.23 (0.95, 1.59) 
  45-54      1.91 (1.42, 2.56) 3.18 (2.27, 4.45)   1.51 (1.18, 1.92) 1.87 (1.45, 2.42) 
  55+ 3.51 (2.64, 4.66) 5.18 (3.75, 7.17)   1.92 (1.49, 2.47) 2.20 (1.69, 2.86) 
Currently living in Phnom Penh  1.13 (0.81, 1.57) 1.68 (1.15, 2.46)   1.17 (0.86, 1.58) 1.47 (1.05, 2.06) 
  (ref. in provinces)           
2 or more behavioral risk factors‡ 0.58 (0.44, 0.76) 0.96 (0.71, 1.31)   0.70 (0.56, 0.87) 0.88 (0.69, 1.13) 
BMI (ref. normal weight)           
  Underweight  0.77 (0.55, 1.08) 0.59 (0.41, 0.84)   0.69 (0.52, 0.91) 0.60 (0.45, 0.80) 
  Overweight and obese  1.90 (1.55, 2.33) 1.48 (1.19, 1.84)   1.54 (1.28, 1.84) 1.33 (1.09, 1.60) 
CI, Confidence Interval.  
High cholesterolemia: total cholesterol between ≥ 240 g/dL and/or on cholesterol lowering drugs.  
Borderline-high cholesterolemia: total cholesterol between 200-239 g/dL. 
† Adjusted for sex, age, residence location, behavioral risk factors and BMI.  
‡ Behavioral risk factors include smoking, heavy alcohol consumption, less than 5 servings of fruit and vegetable consumption and l 
ow physical activity. 
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Figure 2-1. Distribution of NCD risk factors among study participants by sex. 
 
Figure 2-2. Association between fasting glucose levels and HIV, stratified by BMI. 
 
58
42
28
33
12
60
3
8
41
27
0
10
20
30
40
50
60
70
< 5 servings of
fruits and
vegetables
Smoker Heavy drinker Overweight/obese Low physical
activity
Male Female
Pe
rc
en
tag
e(
%
)
Source: Data from the 2016 UHS (n=2747) and 2015 KHANA (n=510) STEP surveys, Cambodia
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Figure 2-3. Association between fasting glucose levels and HIV, stratified by sex. 
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Chapter 3. Study 2: 10-year cardiovascular disease (CVD) risk estimation of 
people living with HIV (PLWH) compared with that of the general population 
in Cambodia 
 
3.1. Abstract  
 
Objectives: Cardiovascular Disease (CVD) risk stratification is an important first step to 
informing clinical decisions and preventive efforts for CVD, but rarely assessed in Cambodia. 
Using the Framingham Risk Score (FRS), therefore, we estimated 10-year CVD risk among the 
general population and people living with Human Immunodeficiency Virus or HIV (PLWH) to 
help identify subgroups who should be targeted for CVD prevention.  
Design: Cross-sectional survey.  
Methods: We merged data from two surveys conducted among PLWH (n=499) and the general 
population (n=2383), aged 30 and above, by KHANA Center for Population Health Research 
(nongovernmental organization) in 2015 and by the University of Health Sciences in 2016, 
respectively. Both employed a standardized questionnaire and physical/biochemical 
measurement protocols developed by the World Health Organization (STEPwise Approach to 
Surveillance or STEP survey or STEPS) and were conducted across selected provinces in 
Cambodia. We computed FRS for each individual and performed logistic regression to examine 
the relationship between moderate-to-high 10-year CVD risk and HIV, while adjusting for age, 
sex, residence location, behavioral risk factors and body mass index (BMI). 
Results: We found 18% (n=91) of PLWH and 26% (n=615) of the general population were at 
moderate to high 10-year CVD risk (FRS ≥ 10%). In logistic regression, the odds of moderate-
to-high 10-year CVD were about the same between PLWH and the general population, 
aOR=0.88 (95% CI: 0.60, 1.29).  
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Conclusion: Although PWLH in Cambodia were as likely as the general population to develop 
future CVD, early lifestyle modifications and/or medical intervention targeting them could be 
one of the most cost-effective strategies for future CVD prevention given their regular contact 
with care.  
3.2. Introduction  
 
Deaths from cardiovascular disease (CVD) accounted for the majority of mortality in 
both the general population and people living with Human Immunodeficiency Virus or HIV 
(PLWH) (28, 29). In the context of HIV infection, several HIV-related factors, such as 
antiretroviral therapy (ART) and the HIV virus were hypothesized to directly increase the risk of 
CVD or alter the traditional CVD risk factor profile among this population, rendering them, 
therefore, more susceptible to develop atherosclerosis and other cardiovascular anomaly (45, 92). 
Multiple risk assessment platforms are available and recommended for use to estimate the 10-
year CVD risk among the general population, but only one was developed specifically for 
PLWH (28, 42, 43).  
More general 10-year CVD risk estimation models including the Framingham Risk Score 
(FRS) or the Atherosclerotic Cardiovascular Disease score (ASCVD) were generally 
recommended by experts for regular CVD risk assessment among PLWH (34, 43, 45). For this 
population, especially, in the era of ART, the importance of CVD risk assessment cannot be 
overlooked.  
Being able to stratify subgroups of population according to their CVD estimated risk can 
help guide clinical management and intervention efforts, and, therefore, is an essential step to 
CVD prevention (34, 93). However, most CVD assessment studies pertaining to HIV 
populations were from high-income countries (HICs) (85).  
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In Cambodia, CVD accounted for about one-third of total deaths from NCDs, but the 
World Health Organization estimated that CVD risk assessment might be offered in less than 
25% of the population at primary healthcare providers. (23).  
Therefore, using the FRS, the proposed study aims to assess the 10-year CVD risk among 
the general population and those who are living with HIV in Cambodia in order to help identify 
those who might be at higher risk of future CVD events. This assessment could help inform 
lifestyle and/or medical interventions that should be proposed as well as the population that 
should be targeted.  
3.3. Methods  
 
We merged STEP4 surveys conducted by the University of Health Sciences (UHS) in 
2016 (n=2383) and by KHANA Center for Population Health Research in 2015 (n=499), 
respectively, among those aged 30 and above. Both surveys had > 90% response rates and 
included information on socio-demographics, behavioral risk factors, and measurements of blood 
pressure, total cholesterol, and glucose levels. Blood pressure was measured three times, five 
minutes apart, and the average was used for high blood pressure classification. Both glucose and 
total cholesterol levels were measured in the morning before breakfast and after fasting the night 
before. Physical activity (recreation- or work-related) included locally-adapted activities, such as 
farming and household chores. Body Mass Index (BMI) classification was based on Asian-
specific cutoffs.  
The details of the KHANA’s STEP survey were described elsewhere (14). It should be 
noted that, while KHANA conducted their survey at designated HIV clinics across 4 provinces 
 
 
4 The World Health Organization (WHO) ‘s standardized questionnaire and measurement protocols called the 
STEPwise approach to NCD risk factor surveillance - STEP survey or STEPS. 
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and the capital city, UHS STEP survey was a national household survey. The data collectors for 
both surveys were a mixture of medical (mostly nurses) and non-medical personnel and had 
undergone appropriate training with human subjects certified trainers of their corresponding 
institutions.  
Regarding the Framingham Risk Score, the calculation was based on the equations 
available on the Framingham study website (https://www.framinghamheartstudy.org/fhs-risk-
functions/cardiovascular-disease-10-year-risk/). The conventional Framingham risk prediction 
models include age, sex, systolic blood pressure, diabetes status, smoking status, hypertension 
treatment status and BMI (94).  
Definition and classification (72-76) 
Definition and classification of variables are as follow: 1) smokers refer to current (daily 
or not) users of any tobacco products. 2) heavy drinkers refer to those who had, during the past 
week: 4 standard drinks5 or more on any one occasion or 14 standard drinks or more in total 
(men), or 3 standard drinks or more on any one occasion or 7 standard drinks or more in total 
(women). 3) fruit and vegetable consumption refer to any one-day consumption on a typical 
week within the past year. 4) low physical activity refers to less than 75 minutes of work or 
recreation activity of vigorous intensity per week or less than 150 minutes of recreation activity 
of moderate intensity per week. 5) nutritional status – underweight refers to BMI < 18.5, normal 
weight refers to BMI between 18.5 and 23, overweight and obese refers to BMI ≥ 23 and BMI ≥ 
25, respectively. 6) Hypertension: mean systolic blood pressure (SBP) ≥ 140 mmHg and/or mean 
diastolic blood pressure (DBP) ≥ 90 mmHg and/or on anti-hypertensive drugs. 7) Diabetes: 
 
 
5 A standard drink is defined as one with a net content of approximately 10g of pure ethanol (in accordance with the 
WHO’s STEP survey showcards’ contents).  
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fasting glucose ≥ 126 mg/dL and/or on anti-diabetic drugs. 8) Prediabetes: fasting glucose 
between 101-125 mg/dL. 9) Prehypertension: mean SBP between 120-139 mmHg and/or mean 
DBP between 80-89 mmHg. 10) High cholesterolemia: total cholesterol between ≥ 240 mg/dL 
and/or on cholesterol lowering drugs. 11) Borderline-high cholesterolemia: total cholesterol 
between 200-239 mg/dL. 12) 10-year CVD risk: Low – FRS < 10%, moderate – FRS between 
10-20% and high – FRS > 20%.  
Power calculation and statistical analysis 
With the total sample size of 2882, the present study has 92% power to detect a 
difference in proportion of moderate-to-high 10-year CVD risk between the two groups.  
We calculated the for each individual the FRS using the equations provided on the 
Framingham heart study website6 and categorized them as low (FRS < 10%), moderate (FRS 
between 10-20%) and high (FRS > 20%) 10-year CVD risk. It should be noted that the FRS can 
only be calculated for subjects aged 30 years or older and with systolic blood pressure (SBP) of 
90 mmHg at the minimum. We, therefore, replaced those with SBP less than 90 mmHg with 90 
mmHg as value for their SBP (n=36). 
We also calculated percentages and means for other categorical and continuous variables, 
respectively, by their FRS category. Logistic regression was performed to examine the 
association between moderate to high 10-year CVD risk (i.e. FRS ≥ 10%) and HIV. We reported 
both the crude and adjusted odds ratios (ORs), controlling for other covariates including age, sex, 
residence location (Phnom Penh or provinces), behavioral risk factors (smoking, heavy drinking, 
 
 
6 https://www.framinghamheartstudy.org/fhs-risk-functions/cardiovascular-disease-10-year-risk/ 
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less than 5 servings of fruits and vegetables, low physical activity) and BMI. All analyses were 
performed using STATA 14 (Copyright 1985-2015 StataCorp LLC). 
Ethical considerations 
The current study was approved by the Institutional Review Board of the University of 
California Los Angeles (UCLA IRB#18-001789) in 2018 and the National Ethics Committee for 
Health Research in Cambodia (NECHR #010) in 2019. All study volunteers provided verbal and 
written consents and understood that no identifying information or blood sample had been 
collected or stored.  
3.4. Results  
 
We had a total of 2882 study participants, aged between 30-78 years. We presented in 
Table 3-1 the study population’s characteristics of PLWH and the general population, among 
those who had FRS < 10% (i.e. low 10-year CVD risk) and those with FRS ≥ 10% (i.e. moderate 
to high 10-year CVD risk).  
We observed that men made up 78% (n=71) and 62% (n=379) of our study sample, 
among PLWH and the general population, respectively, among those with moderate-to-high 10-
year CVD risk. In the low 10-year CVD risk, however, female participants accounted for about 
77% in both population groups. The mean age for both groups was 43 years for those in the low 
10-year CVD risk category, but was older for those in the moderate-to-high 10-year CVD risk 
category, although much older for the general population (57 years, SD=8) than PLWH (54 
years, SD=8). Regardless of their 10-year CVD risk, lower educational background was more 
common among the general population, while unemployment was more prevalent among 
PLWH. We also noted that the majority of participants from both groups reported living in the 
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provinces, but this was more significant among the general population in both low and moderate-
to-high 10-year CVD risk groups.  
In addition, we showed the distribution of CVD risk – low, moderate and high – among 
the study population by age groups in Figure 3-1. For both groups, the youngest age group (30-
44 years) saw extremely low percentage of participants classified as having moderate (FRS 
between 10% and 20%) and high (FRS > 20%) CVD risk in the next 10 years; the majority of 
them were at low 10-year CVD risk (FRS < 10%) (Figure 3-1). However, the percentage went 
up as the age increased. Slightly more general population than PLWH in the 45-54 age group 
were in moderate and high 10-year CVD risk. However, in the 55+ group, more PLWH had 
moderate (34% (n=22)) and high (27% (n=17)) 10-year CVD risk, compared with 31% (n=218) 
for moderate and 24% (n=168) for high 10-year CVD risk among the general population.  
CVD behavioral and metabolic risk factors 
Among those who had moderate-to-high 10-year CVD risk, heavy alcohol consumption 
was more frequent among the general population, 24% (n=56), compared with 11% (n=6) in 
PLWH, while low physical activity was more frequent among PLWH, 27% (n=14), vs. 16% 
(n=55) in the general population. Smoking prevalence was similar, 44% (n=40) in PLWH, vs. 
40% (n=249) among the general population). 
In terms of metabolic risk factors, we observed that, with the exception of diabetes (and 
prediabetes), compared with PLWH, more general population participants were 
overweight/obese, 48% (n=294), vs. 28% (n=26) among PLWH. Details of both behavioral and 
metabolic risk factors for CVD can be found in Table 3-1.  
We also presented the distribution of CVD metabolic risk factors only among those who 
were estimated to have moderate-to-high 10-year CVD risk in Figure 3-2. We noted a 
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significantly larger proportion of PLWH (than the general population) with prediabetic condition 
had been estimated to have moderate-to-high 10-year CVD risk.  
Distribution of HIV-specific factors by estimated 10-year CVD risk  
In Table 3-2, we noted that, regardless of their 10-year CVD risk category, our PLWH 
were mostly on (Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-Nucleoside 
Reverse Transcriptase Inhibitors (NNRTIs) regimen, while regimen with Protease Inhibitors 
(PIs) accounted for 5% or less. Other HIV-specific factors were mostly characteristics 
compatible with prevalent HIV cases (larger proportion of those living with HIV ≥ 60 months 
and having been on ART ≥ 24 months). However, there appeared to be no association between 
any HIV-specific factors and moderate-to-high 10-year CVD risk (Table 3-2).  
Association between 10-year CVD risk and HIV status  
We reported in Table 3-3 the crude and adjusted odds ratios (ORs) examining the 
relationship between moderate-to-high 10-year CVD risk among the general population and 
those living with HIV from two separate models with slightly different sets of adjustment 
variables. One included in adjustment sex, age, residence location, behavioral and metabolic 
disorders (high blood pressure, high blood glucose and total cholesterol levels), while the other 
excluded these metabolic disorders. In both models, the odds of having a 10-year CVD-FRS ≥ 
10% were comparable between PLWH and the general population, aOR=0.68 (95% CI: 0.44, 
1.05), for the model included metabolic disorders, and aOR=0.88 (95% CI: 0.60, 1.29), for the 
model excluded them.  
3.5. Discussion  
 
Although increased CVD risk had been linked with HIV infection and ART in several 
large cohort studies, this association was not consistent across all studies (95). Our overall 
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findings suggested that PLWH did not appear to be at higher odds of CVD events in the next 10 
years than the general population.  
Although we did not show the results, the average FRS was 5.66% among PLWH and 
7.64% among the general population. A 2013 study in South Korea reported similar results with 
the average 10-year CVD risk of 7.07% and 6.87% among PLWH and participants who were 
HIV-negative, respectively (91). Several past studies with similar findings suggested that many 
PLWH were considered a low risk group (i.e. they generally had lower prevalence of CVD 
traditional risk factors, such as smoking and overweight/obesity) and that this could possibly 
explain a low predicted 10-year risk among this population compared with the general 
population (91). The fact that PLWH were actually in regular care (in the context of their HIV 
infection) might have a good influence on their lifestyle behaviors. The majority of PLWH (96% 
(n=481) reported having received three or more lifestyle advices form their providers in the last 3 
years, while only 41% (n=970) of the general population reported so (result not shown).  
PLWH in our study sample consisted mainly of those who had been living with HIV for 
at least 60 months; the average duration of HIV infection was about 10 years (Table 3-2). There 
was little contrast in terms of ART regimen, making it impossible to examine if the predicted 
risk differs significantly across the ART drug regimens. However, a few past studies found no 
significant difference in the predicted CVD risk and ART regimen (91, 96).  
On the contrary, another South Korean study published in 2017 (Kim et al.) found that, 
according to their calculated FRS, a larger percentage of PLWH had higher moderate-to-high 10 
year CVD risk (i.e. FRS of 10% or higher) compared with the general population (29.3% vs. 
19.5%), even though they eventually concluded that the difference was not statistically 
“significant” (85). It should be noted that the distribution of traditional risk factors presented in 
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this study by Kim et al. was quite different in their study population compared to ours. About 
70% of their study population were smokers (regardless of HIV status), and mean BMI as well as 
mean fasting blood glucose were higher among PLWH compared with those who were HIV-
negative (91). The general population in our study, however, had similar mean BMI to that of 
PLWH (approximately 22), but lower fasting blood glucose, and slightly higher smoking 
prevalence (17% vs. 15% in PLWH). A substantially different prevalence of smokers in our 
study and a study by Kim et al. described earlier (91) could explain a larger proportion of PLWH 
with of high 10-year CVD risk among their PLWH compared to ours.  
We would like to also emphasize that our general population group came from a 
household STEP survey, it might have been the case that the survey selectively captured a lot 
more population who were not healthy and, therefore, more likely to be home.   
Limitations  
 
There are also several limitations to our study. First, the equations we used to calculate 
CVD risk score in the present study did not take into account HIV-specific factors, such as CD4 
cell count or ART regimen, and had not been validated for use in PLWH. Nevertheless, the risk 
prediction model that incorporated HIV-specific factors (D:A:D model) had not been validated 
for PLWH and some also argued that the model’s predictive ability did not appear to improve 
even after adding these HIV-specific factors (43). Second, despite the lack of validation of the 
D:A:D risk prediction model for use in PLWH population, the use of FRS to predict the 10-year 
CVD risk among PLWH had not been a general consensus. Recalibration of the FRS might still 
be necessary for a better risk predictive ability. However, as of 2017, the European Clinical Aids 
Society’s (ECAS) guideline still recommended the use of FRS for PLWH for their CVD risk 
assessment (97). Furthermore, the FRS had been validated in Chinese population and widely 
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tested in European and North American populations (38). Lastly, because we were not able to 
ascertain the HIV status for our participants in the general population, misclassification of HIV 
status might have occurred to some degrees. Nevertheless, the prevalence of HIV among the 
general population is less than 1% in Cambodia, the amount of misclassification, if there is any, 
seems to be too small to alter any associations we observed.  
Conclusion 
Based on the Framingham CVD risk prediction models, PLWH appeared to be as likely 
as the general population to have moderate-to-high CVD risk in the next 10 years. However, a lot 
more prediabetic PLWH than the general population were estimated to have moderate-to-high 
10-year CVD risk. This underlines the possible complex interaction between different 
behavioral/metabolic risk factor, biologic factors and HIV-specific factors. PLWH might be at 
high risk of CVD events in the future with elevated blood glucose levels even when they are not 
yet diabetic. Therefore, provided that PWLH undergo regular medical check-up as part of their 
HIV care, regularly perform CVD risk stratification while focusing on modifiable lifestyle 
behaviors and/or simple medical interventions (if applicable) could help combat present and 
future morbidity and mortality related to NCDs as well as CVD among this population.   
3.6. Tables and figures  
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Table 3-1. Key characteristics of study participants by their estimated 10-year CVD risk, STEPS, 
Cambodia, 2015/2016.  
 
Characteristics 
FRS < 10%  FRS ≥ 10%  
PLWH 
(n=408) 
General 
Population 
(n=1768) 
PLWH 
(n=91) 
General 
Population
(n=615) 
Socio-demographics  n % n % n % n % 
Gender          
 Male  95 23.3 411 23.3 71 78.0 379 61.7 
 Female  313 76.7 1357 76.8 20 22.0 235 38.3 
Age (mean, SD) (43.3, 6.8) (43.7, 10.0) (53.6, 7.6) (57.0, 7.7) 
 30-44  236 57.8 1004 56.8 8 8.8 37 6.0 
 45-55  147 36.0 451 25.5 44 48.4 192 31.2 
 55+  24 5.9 313 17.7 39 42.9 386 62.9 
Education           
 None or less than primary 96 23.5 1154 65.3 15 16.5 409 66.5 
 Completed primary 200 49.0 352 19.9 45 49.5 117 19.1 
 Completed secondary 96 23.5 182 10.3 23 25.3 65 10.6 
 Completed high school or higher 16 3.9 79 4.5 8 8.8 24 3.9 
Occupation           
 Salary employed  120 29.4 162 9.2 30 33.0 49 8.0 
 Self-employed  186 45.6 1348 76.2 40 44.0 469 76.4 
 Unemployed  102 25.0 258 14.6 21 23.1 97 15.8 
Marital status           
 Single  3 0.7 63 3.6 1 1.1 10 1.6 
 Married+cohabiting 246 60.3 1399 79.1 65 72.2 485 78.8 
 Separated   5 1.2 48 2.7 1 1.1 5 0.8 
 Divorced   32 7.8 46 2.6 5 5.6 11 1.8 
 Widowed   122 29.9 212 12.0 18 20.0 104 16.9 
Residence location         
 Province  302 74.0 1680 95.0 69 75.8 575 93.5 
 Phnom Penh  106 26.0 88 5.0 22 24.2 40 6.5 
CVD behavioral risk factors           
Smokers   34 8.3 154 8.7 40 44.0 249 40.5 
Heavy drinkers   11 7.1 130 21.7 6 11.3 56 23.8 
< 5 servings of fruits and vegetables  367 90.2 924 52.7 88 96.7 341 55.9 
Low physical activity  82 32.2 142 17.4 14 26.9 55 16.0 
CVD metabolic risk factors         
Body Mass Index (BMI)         
 Normal weight  238 58.5 772 44.7 53 58.2 261 42.4 
 Underweight  85 20.9 243 14.1 12 13.2 60 9.8 
 Overweight and obese  84 20.6 712 41.2 26 27.5 294 47.8 
Blood glucose         
 Prediabetes 203 52.7 271 16.6 47 69.1 86 19.9 
 Diabetes  21 5.2 48 2.9 23 25.3 135 23.8 
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Table 3-1. Key characteristics of study participants by their estimated 10-year CVD risk, STEPS, 
Cambodia, 2015/2016. (continued) 
 
 
 
Table 3-2. HIV-specific factor distribution among PLWH, by estimated CVD risk status (based 
on FRS calculation), STEPS, Cambodia, 2015/2016. 
HIV-specific factors  
Estimated 10-year CVD risk 
Low 
(n=408) 
Moderate-to-high 
(n=91) 
   n (%) n (%) 
On ART 24 months or longer 379 (95.5) 83 (95.4) 
> 350 CD4 cell count 238 (67.2) 54 (65.9) 
ART regimen    
 NRTI and NNRTI 372 (97.4) 81 (95.3) 
 With PI 10 (2.6) 4 (4.7) 
Living with HIV ≥ 60 months  356 (87.3) 78 (85.7) 
Duration of HIV infection (mean, SD)  9.8 (5.5) 9.7 (4.9) 
 NRTI, Nucleoside Reverse Transcriptase Inhibitor. 
 NNRTI, Non-Nucleoside Reverse Transcriptase Inhibitor. 
 PI, Protease Inhibitor. 
 
 
Characteristics 
FRS < 10%  FRS ≥ 10%  
PLWH 
(n=408) 
General 
Population 
(n=1768) 
PLWH 
(n=91) 
General 
Population 
(n=615) 
 n % n % n % n % 
Blood pressure          
 Prehypertension 109 29.4 569 37.7 35 57.4 157 56.3 
 Hypertension   36 8.9 246 14.0 30 33.0 336 54.6 
Total cholesterol          
 Borderline-high 64 16.3 449 33.1 27 30.7 149 34.8 
 High   13 3.2 323 19.2 3 3.3 162 27.4 
SD, Standard Deviation.          
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Table 3-3. Association between moderate-to-high 10-year CVD risk and HIV, STEPS, Cambodia, 2015/016. 
Predictors  
Crude OR 
(95 % CI) 
Adjusted OR† 
(95 % CI) 
 
Adjusted OR‡ 
(95 % CI)  
HIV+ (ref. general population) 0.64 (0.50, 0.82) 0.68 (0.44, 1.05) 0.88 (0.60, 1.29)  
Female (ref. male) 0.17 (0.14, 0.21) 0.03 (0.02, 0.04) 0.05 (0.03, 0.06)  
Age  1.15 (1.14, 1.17) 1.28 (1.25, 1.31) 1.25 (1.23, 1.28)  
Currently living in Phnom Penh  0.98 (0.73, 1.33) 0.79 (0.47, 1.30) 0.97 (0.62, 1.52)  
  (ref. provinces)              
2 or more behavioral risk factors¶ 2.92 (2.40, 3.55) 3.43 (2.45, 4.81) 3.01 (2.21, 4.09)  
BMI (ref. normal weight)              
  Underweight  0.71 (0.53, 0.94) 0.39 (0.25, 0.62) 0.29 (0.20, 0.44)  
  Overweight and obese  1.29 (1.08, 1.55) 1.81 (1.33, 2.46) 2.38 (1.81, 3.15)  
Blood pressure (ref. normal)            
 Hypertension or prehypertension 4.73 (3.87, 5.77) 6.48 (4.67, 8.99) -  
Blood glucose (ref. normal)              
 Diabetes or prediabetes 2.13 (1.78, 2.55) 2.45 (1.80, 3.33) -  
Total cholesterol (ref. normal)              
  High or borderline-high 1.44 (1.21, 1.71) 0.98 (0.73, 1.31) -  
CI, Confidence interval.         
† Adjusted for sex, age, residence location, behavioral risk factors, BMI, diabetes/prediabetic conditions 
and high/borderline-high cholesterolemia. 
‡ Adjusted for sex, age, residence location, behavioral risk factors and BMI. 
¶ Behavioral risk factors include smoking, heavy alcohol consumption, less than 5 servings of fruits and 
vegetable consumption and low physical activity.  
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Figure 3-2. Distribution of metabolic risk factors among those with moderate-to-high 10-year 
CVD risk. 
  
Figure 3-1. Distribution of 10-year CVD risk among study participants by age. 
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Chapter 4. Study 3: Differences in prevalence and risk factors of non-
communicable diseases between young people living with HIV (YLWH) and 
young general population in Cambodia 
 
4.1. Abstract  
 
Background: Young people living with Human Immunodeficiency Virus or HIV (YLWH) in 
Cambodia are a vulnerable, understudied population. The demographic transition, HIV infection 
and its treatments put YLWH more at risk of non-communicable diseases (NCDs). We examined 
the prevalence of NCDs and their risk factors among YLWH and the young general population 
to understand the extent to which HIV contributes to the development of NCDs among YLWH.   
Design: Cross-sectional survey.  
Methods: We gathered information on YLWH, aged 18-29 years, from three HIV clinics in 
Phnom Penh (n=370), and on young general population from the 2016 survey (n=486) conducted 
by the University of Health Science. Both surveys employed a standardized questionnaire and 
physical/biochemical measurement protocols developed by the World Health 
Organization (STEPwise Approach to Surveillance or STEP survey or STEPS). We reported the 
prevalence of hypertension, prehypertension, diabetes, prediabetes, high and borderline-high 
cholesterolemia among the two groups, then performed logistic regression to examine the 
relationship between each of these conditions and HIV, adjusting for age, sex, residence location, 
behavioral risk factors and body mass index (BMI). 
Results: The prevalence of diabetes and hypertension is 4% (n=16) and 6% (n=22), respectively, 
among YLWH, compared to 1% (n=4) and 4% (n=22), among the general population of the 
same age group. YLWH, however, had high prevalence of high cholesterolemia, 20% (n=72), 
compared with young general population 11% (n=49). In logistic regression, after adjustment, 
we observed higher odds of diabetes/prediabetes and high cholesterolemia among YLWH 
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compared with the general population, aOR=6.64 (95% CI: 3.62, 12.19) and aOR=7.95 (95% CI: 
3.98, 15.87), respectively.  
Conclusion: Results from current study highlight the necessary establishment of screening 
measures and readily-available treatment options for certain chronic conditions such as diabetes 
(and prediabetes) and high cholesterolemia, in order to combat high burden of NCDs in the near 
future among this population.  
4.2. Introduction  
 
Adolescents and young adults face major under-addressed behaviors that might pose 
detrimental effects for their adult health status and prevent them from reaching their full 
potentials (98). Many of these unhealthy behaviors, such as smoking, substance abuse, exercising 
and eating habits, were adopted or formed during adolescence and early adulthood, potentially 
predisposing this population to an early obesity (and their related co-morbidities) and eventual 
poor health outcomes in their late adulthood (46-49, 98, 99). In addition, unhealthy lifestyle 
behaviors related to non-communicable diseases (NCDs) have been observed to be more 
common among youth around the world, prompting even the World Health Assembly to call 
upon its member states to address NCD-related issues among young people (99).  
We focus on adolescents for multiple reasons. First, according to the developmental 
origins of health and disease theory, the period during adolescence and young adulthood is 
considered one of the critical periods of for targeting behavioral or medical intervention, as these 
early interventions could maximize the health benefits that would come later in adulthood, i.e. 
preventing the development of chronic diseases (100). Second, these NCDs are fast becoming a 
pressing matter for young people as many of the behaviors that had been associated with NCDs 
and their risk factors are quite prevalent among young people. According to the World Health 
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Organization (WHO), “over 150 million young people smoke, 81% adolescents don’t get enough 
physical activity, and 11.7% of adolescents partake in heavy episodic drinking” (49). Lastly, by 
addressing NCDs among young population now, we are helping to steer the future course of 
NCD morbidity and mortality. This will have economic and logistical consequences on the 
healthcare system, which is particularly fragile in resource-limited settings.  
In Cambodia, studies conducted in the past have often emphasized specific high-risk 
populations, rather than the youth population as a whole, and this especially in the context of 
Human Immunodeficiency Virus (HIV), rather than NCDs (52-59). Moreover, there is increasing 
evidence implicating HIV infection and antiretroviral therapy (ART) in contributing to the 
increased risk of multiple chronic metabolic disorders. These include the glucose (87), and lipid 
disorders for people living with HIV, particularly those in older age (101, 102).  
Because of inadequate research among YLWH in Cambodia, the risk profile and 
prevalence of NCDs among our YLWH had never been comprehensively assessed. The lack of 
epidemiological research among this vulnerable population should not be overlooked.  
Therefore, the present study aimed to examine the differences (or similarities) among 
YLWH and the general population of the same age group in terms of their distribution of NCDs, 
as well as NCD risk factors, to inform research and health policy priorities, as well as to 
determine if specific and early behavioral or medical interventions should be prepared for this 
young population.   
4.3. Methods 
 
Study setting and recruitment  
We conducted a cross-sectional survey and recruited 370 YLW who came for regular 
medical checkup at three HIV clinics in Phnom Penh, Cambodia, from November 2019 – 
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February 2020. In Cambodia, these clinics/hospitals are known as Opportunistic Infections and 
Antiretroviral Therapy sites, designated “OI/ART” sites.  
Information on the general population, on the other hand, was obtained from a subset of 
the STEP7 (household) survey population of the same age group (n=486), which was conducted 
across all provinces in Cambodia by the University of Health Sciences (UHS) and partners in 
2016.  
Both our newly-conducted STEP survey and the 2016 STEP survey gathered information 
on socio-demographics and NCD risk factors, such as smoking, alcohol consumption, diet and 
physical activity. Our STEP survey, however, added information on HIV-specific factors, such 
as ART regimen and duration of ART use, using (de-identified) patients’ personal follow-up 
booklet and/self-reports.  
Participants of both sexes were considered eligible if they were between the age of 18-29 
years and were able to provide verbal consent to the study team at the time of data collection.  
All data collectors underwent training prior to data collection regarding interviewing 
techniques and ethical research principles with human subjects certified trainers. They were also 
trained on study protocol, tablet usage, and measurement techniques/protocols to ensure 
consistency in data collection process.  
Data collection tools and process 
We conducted a Computer-Assisted-Person-Interview (CAPI) using tablets for the 370 
YLWH recruited for our study.  
 
 
7 The World Health Organization (WHO) developed a standardized questionnaire and measurement protocols for the 
surveillance of NCDs and their risk factors, called STEP survey or STEPS. 
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To obtain physical and biochemical measurements on our study volunteers, we employed 
digital scales, OMRONâ Upper Arm Blood Pressure Monitor, measuring tapes and 
BeneCheckâ rapid testing devices. Of note, blood pressure was measured three times, five 
minutes apart, and the average of the three was then calculated. The rapid blood tests (for 
glucose and total cholesterol levels) took less than a minute. Information on whether or not 
participants fasted the night before was also noted for later glucose adjustment for diabetes and 
prediabetes classification.  
Physical activity (recreation- or work-related) included locally-adapted activities, such as 
farming and household chores. Body Mass Index (BMI) classification was based on Asian-
specific cutoffs.  
In general, when the participant had been (verbally) consented, they would be measured 
(weight, height, waist circumference, and blood pressure). Then they underwent rapid blood tests 
(whether or not the participant had been fasting before blood tests will also be noted) so that 
values will be adjusted later for diabetes and prediabetes classification. After physical and 
biochemical measurements, results of these measurements were given back to each participant in 
written letter in case they would like to further discuss with their healthcare provider. In the end, 
the data collector would conduct a face-to-face interview with each individual using a structured 
questionnaire which was administered via tablet.  
Definition and classification (72-76) 
Definition and classification of variables are as follow: 1) smokers refer to current (daily 
or not) users of any tobacco products. 2) heavy drinkers refer to those who had, during the past 
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week: 4 standard drinks8 or more on any one occasion or 14 standard drinks or more in total 
(men), or 3 standard drinks or more on any one occasion or 7 standard drinks or more in total 
(women). 3) fruit and vegetable consumption refer to any one-day consumption on a typical 
week within the past year. 4) low physical activity refers to less than 75 minutes of work or 
recreation activity of vigorous intensity per week or less than 150 minutes of recreation activity 
of moderate intensity per week. 5) nutritional status – underweight refers to BMI < 18.5, normal 
weight refers to BMI between 18.5 and 23, overweight and obese refers to BMI ≥ 23 and BMI ≥ 
25, respectively. 6) Hypertension: mean systolic blood pressure (SBP) ≥ 140 mmHg and/or mean 
diastolic blood pressure (DBP) ≥ 90 mmHg and/or on anti-hypertensive drugs. 7) Diabetes: 
fasting glucose ≥ 126 mg/dL or post-prandial glucose ≥ 200mg/dL and/or on anti-diabetic drugs. 
8) Prediabetes: fasting glucose between 101-125 mg/d or post-prandial glucose between 140-199 
mg/dL. 9) Prehypertension: mean SBP between 120-139 mmHg and/or mean DBP between 80-
89 mmHg. 10) High cholesterolemia: total cholesterol between ≥ 240 mg/dL and/or on 
cholesterol lowering drugs. 11) Borderline-high cholesterolemia: total cholesterol between 200-
239 mg/dL.  
Power calculation and statistical analysis 
With the total sample size of 856 (370 of YLWH and 486 of the general population), the 
present study has more than 90% power to detect a difference in prevalence of diabetes, 
prediabetes, high and borderline-high cholesterolemia, between the two groups.  
For analysis, we calculated the prevalence of hypertension, prehypertension, diabetes, 
prediabetes, high and borderline-high cholesterolemia as well as percentages and means for 
 
 
8 A standard drink is defined as one with a net content of approximately 10g of pure ethanol (in accordance with the 
WHO’s STEP survey showcards’ contents).  
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categorical and continuous variables, respectively, among YLWH and the general population. 
We fitted a separate logistic regression model to examine the association between each of the 
conditions listed above and HIV; we reported the crude and adjusted odds ratios (ORs), the latter 
controlled for other covariates including age, sex, residence location (Phnom Penh vs. 
provinces), behavioral risk factors (smoking, heavy drinking, less than 5 servings of fruits and 
vegetables, low physical activity) and BMI. All analyses were performed using STATA 14 
(Copyright 1985-2015 StataCorp LLC).   
Ethical considerations 
The current study was approved by the Institutional Review Board of the University of 
California Los Angeles (UCLA IRB#19-000272) and the National Ethics Committee for Health 
Research in Cambodia (NECHR #129) in 2019. All study volunteers provided verbal and 
understood that no identifying information or blood sample had been collected or stored.  
4.4. Results  
 
Socio-demographics  
Overall, there were 370 participants who were living with HIV and 486 general 
population participants (total N=856) aged between 18-29 year. Table 4-1 detailed all the socio-
demographics and the NCD risk factor distribution.  
We found that about 70% (n=254) of participants who are living with HIV were male, 
whereas, female participants accounted for 70% (n=344) of the general population. The average 
age was 23 years (SD=3.2) and the median was 23 years (IQR=6) among YLWH, while the 
average and median age were 24 years (SD=3.3) and 25 years (IQR=6), respectively, among the 
general population. In terms of education, more YLWH reported having had completed at least 
high school (58% (n=210)) while only 15% (n=72) of the young general population reported so. 
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However, those who were unemployed accounted for about 20% in each group, the rest was 
either self- or salary-employed. We also noted a huge difference in terms of residence types 
reported between the two groups. About 95% (n=468) the young general population, but only 
23% (n=85) of YLWH reported that their current residence was in the provinces.  
NCD risk factor distribution  
We observed that the prevalence of smoking was low (less than 10% in both groups) and 
heavy alcohol consumption differed only slightly among the two groups (20% (n=52) among 
YLWH vs. 23% (n=37) among the general population). Although consumption of low fruits and 
vegetable consumption and low physical activity were more common among YLWH compared 
to the young general population, we observed that the number of those who were overweight and 
obese were higher in the young general population group (24% (n=109)) than YLWH  
(16% (n=57)) (Table 4-1). Obesity was 7% (n=24) among YLWH and 12% (n=55) among the 
general population (result not shown). The prevalence of diabetes and hypertension is 4% (n=16) 
and 6% (n=22), respectively, among YLWH, compared to 1% (n=4) and 4% (n=22), among the 
general population. In addition, YLWH presented more prevalent cases of high total blood 
cholesterol (20% (n=72)) compared with the young general population (11% (n=49)). Other 
metabolic abnormalities are elaborated in Table 4-1.  
We presented in Table 4-2 the distribution of HIV-specific factors by glucose, blood 
pressure and total cholesterol status. Of note, only high or borderline-high cholesterolemia 
emerged to be associated with longer duration of ART use (24 months or longer), combination 
NRTI and NNRTI therapy, perinatal HIV infection and longer duration of HIV infection (60 
months or longer) (Table 4-2). For further illustration, we also presented in Figure 4-4 the 
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distribution of these HIV-specific factors among those with normal and elevated total cholesterol 
levels.  
Association between NCDs and HIV 
Diabetes or prediabetes  
We grouped diabetes or prediabetes in order to ensure sufficient number of outcomes 
across exposure status and other adjusting variables (the number of diabetic cases alone is low in 
both groups). Without adjusting for potential confounders, YLWH were nine times more likely 
than the general population to present diabetes or prediabetes, cOR=9.59 (95% CI: 6.15, 14.95). 
After adjusting for potential confounders (sex, age, current residence location, behavioral risk 
factors and BMI), YLWH remained at significantly higher odds of diabetes or prediabetes 
compared with the general population, aOR=6.64 (95% CI: 3.62, 12.19) (Table 4-3).  
We also presented the boxplots depicting the relationship between fasting plasma glucose 
levels and HIV, stratifying on BMI status and sex in Figure 4-1 and Figure 4-2, respectively. 
Regardless of BMI and sex, YLWH appeared to have a higher fasting plasma glucose levels 
compared to the young general population.  
Hypertension and prehypertension and HIV 
In crude analysis, the crude ORs appeared to suggest a positive association between both 
hypertension and prehypertension and HIV, cOR=1.60 (95% CI: 1.17, 2.18) and cOR=1.36 (95% 
CI: 0.74, 2.50), respectively. However, after adjustment was made (Table 4-4), YLWH were no 
longer at higher odds of these conditions compared with the young general population, 
aOR=1.01 (95% CI: 0.59, 1.71) for prehypertension and aOR=0.41 (95% CI: 0.13, 1.27) for 
hypertension.  
High and borderline-high cholesterol  
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We presented in Table 4-5 the association between total cholesterol levels and HIV 
among ALL study participants (including those who did not fast before rapid blood tests). 
YLWH were twice (before adjusting for covariates) and almost eight times (after adjustment) 
more likely than the young general population to present high cholesterolemia, the crude and 
adjusted ORs were, respectively, cOR=2.04 (95% CI: 1.37, 3.02) and aOR=7.95 (95% CI: 3.98, 
15.87). The odds of borderline-high cholesterolemia did not appear to be different among the two 
groups, aOR=0.98 (95% CI: 0.45, 2.15). Although we showed here only the results among ALL 
participants for high and borderline-high cholesterolemia, all of these above associations 
between total cholesterol and HIV remained largely unaffected with or without inclusion of those 
who did not fast before rapid blood tests.  
We also showed in Figure 4-3 the (fasting) total cholesterol levels among study 
participants by BMI status and sex. Higher total cholesterol was observed among YLWH 
regardless of sex and BMI status.  
4.5. Discussion  
 
Our findings on NCDs confirm that from other studies conducted in different parts of the 
world, although few have examined young people living with HIV under the same age range as 
ours (18-29 years).  
First, the prevalence of hypertension was 6% among our YLWH, which is lower than the 
8% and 12.4% reported in Ugandan studies conducted in Rakai and Lubowa, respectively (103, 
104). However, these two studies recruited a much older population, the mean age for the Rakai 
study population was about 38 year for women and 42 years for men (103), both of which are 
more than 10 years older than our YLWH’s mean age. The population under study in Lubowa, 
on the other hand, was composed of only 11% of those under the age of 30 (104). Because age is 
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known to be positively associated with high blood pressure regardless of HIV status, we would 
expect a lower prevalence in our study compared to theirs. 
We also found comparable diabetes prevalence in our study (4.6%) as the study 
conducted in Lubowa (Uganda) which reported a prevalence of 4.7% (104). However, taking 
into account the difference in the age constitution of both study populations (much older PLWH 
in their study compared to ours), it is likely that the actual prevalence between the two studies 
might have been different. Additionally, the study in Lubowa defined diabetes with a much 
higher threshold of fasting plasma glucose (140 mg/dL or higher), leading to a small number of 
diabetes cases (104), despite having a much older population in the study.  
However, a recently published paper, using data collected from HIV clinics at the 
University of Maryland Medical System and the University of Maryland Family Medicine 
Program, reported a much higher prevalence of hypertension (23.1%) but a lower prevalence of 
diabetes (2% to 4%) compared to ours (105). Although this study was also conducted among 
those aged between 18-29 years, the smoking and alcohol consumption rates were very high 
(about 60% for both) (105).  
We noted higher prevalence of high cholesterolemia in our YLWH, contrasting to 
findings from the 2015 STEPS, conducted among older PLWH (14). This could be due to an 
increase in the Protease-Inhibitor- or PI-based regimen use among children (from only 5% in 
20099 to 13%in 201610, based on reports from the National Center for HIV/AIDS, Dermatology 
and STDs (NCHADS). PIs were frequently linked with dyslipidemia (37, 45).  
 
 
9 Annual Report 2009. MOH/NCHADS. Cambodia. 2009.  
10 Annual Report 2016. MOH/NCHADS. Cambodia. 2016. 
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Second, our general population group came from a household STEP survey, it might have 
been the case that the survey selectively captured a lot more population who were not healthy 
and, therefore, more likely to be home.  
Third, the difference in traditional (behavioral) risk factor distribution among population 
living with HIV could be due partially to difference in income levels and other demographic 
factors in different study settings might as well explain these differences in NCD prevalence 
across studies. About 70% of our YLWH were men, a finding that is also contrasting to that of 
the 2015 STEP survey conducted among older PLWH in Cambodia (14). However, our survey 
was conducted only in Phnom Penh (capital city) and our study population was also much 
younger. As the country increasingly opens up to gay and transgender community and more HIV 
clinics begin to offer services tailored to their health needs, more of these individuals also start 
coming out and seeking care. Therefore, the 2015 STEP survey captured an older generation of 
PLWH (a lot of whom had been infected behaviorally), while our study population was a 
younger generation of PLWH (an equal mixture of both behaviorally and perinatally infected 
individuals).  
Lastly, definitions and terms used for each of these conditions might slightly differ from 
one study to another, and quietly possibly there were variations between blood tests. Other 
factors related to HIV infection, such as acquiring HIV perinatally or behaviorally (Table 4-2) 
might be associated with other NCD risk factors, and, therefore, also drive some of these 
differences in NCD prevalence. Although, there appeared to be no association between any of 
these HIV-specific factors and elevated blood glucose or blood pressure (Table 4-2) and the 
distribution of NCD behavioral risk factors did not appear to significantly differ among our 
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YLWH who were perinatally infected and those who were behaviorally infected (result not 
shown). 
Limitations  
First, given the nature of our study design, we understand that we have to be careful when 
interpreting our findings regarding the association between HIV and NCDs, in causal 
terminology. Nevertheless, these results were consistent with that of multiple studies including 
those of longitudinal nature, such as the MACS cohort study, affirming the plausibility that the 
relationship observed here might be close to the underlying true relationship. In addition, about 
half of YPLW in the study sample were perinatally-infected and the average duration of HIV 
infection was about 9 years. Taking this as well as their age into consideration, we can 
reasonably assume that their metabolic disorders are more likely to occur after the onset of HIV 
infection and ART. Besides, we also saw that the NCD prevalence among those perinatally 
infected and behaviorally infected did not significantly differ, particularly in the case of 
diabetes/prediabetes and hypertension/prehypertension.  
Second, because we were not able to ascertain the HIV status for our participants in the 
general population, misclassification might have occurred. However, the prevalence of HIV 
among the general population is less than 1% in Cambodia, the amount of misclassification (if 
any) should be negligible.  
Third, we lacked detailed lipid profile as our rapid tests were only capable of measuring 
total cholesterol. Low-density lipoprotein or high-density lipoproteins cholesterol (LDL-Chol or 
HDL-Chol) as well as triglycerides were not captured. Our study could then only provide first 
look on the overall fat profile among this population.  
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Lastly, there were several covariates related to the NCDs that were not measured in the 
original STEP survey conducted among the general population, including oral contraceptive use 
(for women) and birth history (prematurity or low birth weight). As a result, we could not 
account for any of these factors in the analysis. Nevertheless, the focus of the STEP survey is the 
modifiable lifestyle factors, many of which were indeed included in logistic regression model. 
Moreover, the majority of our YLWH were males and although we didn’t show in results, over 
80% of our female participants reported no use of oral contraceptives at the time of data 
collection.  
Conclusion 
 
Young population living with HIV in Cambodia, mainly in the capital city (Phnom Penh), 
face multiple metabolic disorders and NCDs despite their young age and lower prevalence of 
traditional risk factors such as smoking and alcohol consumption compared with general 
population of the same age group. The prevalence of glucose disorders (diabetes and prediabetes) 
and high cholesterolemia were significantly higher among our YLWH compared with the young 
general population, while hypertension prevalence between the two groups appeared comparable.  
The current study’s results highly suggest that HIV infection and ART might have 
important roles in contributing to the early development of chronic diseases, such as diabetes, 
prediabetes and high cholesterolemia, in addition to the conventional NCD risk factors. Further 
investigations including detailed lipid profile assessment (including LDL-Cholesterol, HDL-
Cholesterol and triglycerides) might be necessary to fully comprehend the extent to which HIV-
specific factors affect various forms of fats. Furthermore, the Cambodian ART regimen guideline 
needs further exploration and discussions; there needs to be studies that are designed specifically 
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to assess the effects of various ART drugs on these metabolic chronic disorders, especially that 
of glucose and cholesterol.  
Understanding the contributions of these HIV-specific factors to an increase in chronic 
disease risk and putting in place early proper screening as well as treatment measures for certain 
metabolic disorders (mainly prediabetes, diabetes and high total cholesterolemia) targeting this 
young population group might be one of the most effective strategy to combat NCD morbidity 
and mortality in the long term.   
4.6. Tables and figures  
Table 4-1. Key characteristics of study participants, STEPS, Cambodia, 2016 and 2019/2020. 
Socio-demographics  
YLWH 
(n=370) 
Young General 
Population 
(n=486) 
 
 
      n % n %  
Gender            
  Male   254 70.8 146 29.8  
  Female   105 29.2 344 70.2  
Age (mean, SD) (23.1, 3.2) (24.1, 3.3)  
Education             
  None or less than primary 7 1.9 177 36.1  
  Completed primary 41 11.4 136 27.8  
  Completed secondary 101 28.1 105 21.4  
  Completed high school or higher 210 58.5 72 14.7  
Occupation             
  Salary employed  211 58.8 64 13.1  
  Self-employed  70 19.5 312 63.7  
  Unemployed  78 21.7 114 23.3  
Marital status             
  Single   315 87.7 149 30.4  
  Married+cohabiting 40 11.1 322 65.7  
  Other   4 1.1 19 3.4  
Residence types          
  Province   85 23.5 468 95.5  
  Phnom Penh  277 76.5 22 4.5  
NCD behavioral risk factors        
Smokers    17 4.7 32 6.5  
Heavy drinkers  52 19.6 37 23.3  
< 5 servings of fruits and vegetables  232 65.9 245 50.1  
Low physical activity  81 38.9 44 20.4  
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Table 4-1. Key characteristics of study participants, STEPS, Cambodia, 2016 and 2019/2020. 
(continued) 
 
Characteristics  
YLWH 
(n=370) 
Young General 
Population 
(n=486) 
 
NCDs   n % n %  
Body Mass Index (BMI)          
  Normal weight  210 58.2 251 55.6  
  Underweight  94 26.0 91 20.2  
  Overweight and obese  57 15.8 109 24.2  
Blood glucose            
  Prediabetes† 120 34.0 23 5.2  
  Diabetes†   16 4.5 4 0.9  
  Fasting blood glucose‡ (mean, SD) (105.6, 26.3) (80.8, 19.6)  
Blood pressure           
  Prehypertension   114 31.6 111 23.0  
  Hypertension   22 6.1 22 4.5  
  SBP‡ (mean, SD) (113.4, 12.0) (110.0, 11.3)  
  DBP‡ (mean, SD) (75.2, 8.1) (72.4, 9.1)  
Total cholesterol           
  Borderline-high† 34 12.2 82 21.0  
  Borderline-high¶ 22 12.9 82 21.0  
  High†   72 20.4 49 11.2  
  High¶   47 21.7 49 11.2  
  Fasting total cholesterol‡ (mean, SD)   (189.4, 63.1) (179.7, 49.4)  
SD, Standard Deviation.  
† Included ALL participants. 
‡ Excluded those currently on treatment for each specified condition. 
¶ Included ONLY fasting participants. 
 
Table 4-2. Distribution of HIV-specific factors by NCD status, STEPS, Cambodia, 2016 and 
2019/2020. 
   Diabetes or 
prediabetes  
Hypertension or 
prehypertension 
High or borderline-
high cholesterolemia 
   n (%) n (%) n (%) 
On ART 24 months or longer 80 (59.3) 74 (55.2) 79 (75.2)*** 
Less than 350 CD4 cell count 51 (76.1) 49 (67.1) 30 (69.8) 
NRTI and NNRTI (vs. other) 42 (70.0) 49 (65.3) 48 (82.7)** 
Perinatally infected  62 (47.0) 58 (43.3) 60 (59.4)** 
 (vs. behaviorally infected)    
Living with HIV ≥ 60 months  73 (54.1) 68 (50.7) 71 (67.6 )** 
Duration of HIV infection (mean, SD) 8.6 (8.3) 8.6 (8.6) 10.9 (8.2)** 
 NRTI, Nucleoside Reverse Transcriptase Inhibitor. 
 NNRTI, Non-Nucleoside Reverse Transcriptase Inhibitor. 
 *, **, *** refers to a p-value ≤ 0.05, ≤ 0.01, and ≤ 0.001, respectively. 
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Table 4-3. Association between diabetes/prediabetes and HIV, STEPS, Cambodia, 2016 and 
2019/2020. 
 
Predictors  
Diabetes or Prediabetes 
Crude OR 
(95% CI) 
Adjusted OR† 
(95% CI)  
HIV+ (ref. young general population) 9.59 (6.15, 14.95) 6.64 (3.62, 12.19)  
Female (ref. male) 0.29 (0.20, 0.42) 0.67 (0.44, 1.03)  
Age  0.94 (0.90, 1.00) 0.96 (0.91, 1.03)  
Current address in Phnom Penh  5.44 (3.76, 7.89) 1.33 (0.81, 2.21)  
  (ref. in provinces)      
2 or more behavioral risk factors‡ 1.78 (1.17, 2.71) 1.17 (0.73, 1.86)  
BMI (ref. normal weight)      
  Underweight  0.62 (0.40, 0.99) 0.49 (0.29, 0.81)  
  Overweight and obese  0.92 (0.59, 1.44) 1.19 (0.72, 1.98)  
CI, Confidence interval.  
Diabetes: fasting glucose ≥ 126 mg/dL or post-prandial glucose ≥ 200mg/dL and/or 
on anti-diabetic drugs.  
Prediabetes: fasting glucose between 101-125 mg/d or post-prandial glucose 
between 140-199 mg/dL.  
† Adjusted for sex, age, residence location, behavioral risk factors and BMI.  
‡ Behavioral risk factors include smoking, heavy alcohol consumption, less than 5  
servings of fruit and vegetable consumption and low physical activity. 
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Table 4-4. Association between hypertension and prehypertension and HIV, STEPS, Cambodia, 2016 and 2019/2020. 
Predictors 
Hypertension    Prehypertension 
Crude OR 
(95% CI) 
Adjusted OR† 
(95% CI) 
  Crude OR 
(95% CI) 
Adjusted OR† 
(95% CI) 
HIV+ (ref. young general population) 1.36 (0.74, 2.50) 0.41 (0.13, 1.27)   1.60 (1.17, 2.18) 1.01 (0.59, 1.71) 
Female (ref. male) 0.36 (0.18, 0.70) 0.38 (0.17, 0.83)   0.31 (0.22, 0.43) 0.28 (0.19, 0.42) 
Age  1.12 (1.02, 1.23) 1.09 (0.99, 1.21)   1.06 (1.01, 1.12) 1.06 (1.01, 1.12) 
Current address in Phnom Penh  1.91 (1.04, 3.51) 3.54 (1.21, 10.41)   1.41 (1.02, 1.94) 1.18 (0.70, 1.97) 
  (ref. in provinces)           
2 or more behavioral risk factors‡ 2.12 (1.08, 4.17) 1.70 (0.82, 3.56)   1.19 (0.79, 1.78) 0.89 (0.57, 1.40) 
BMI (ref. normal weight)           
  Underweight  0.66 (0.21, 2.01) 0.73 (0.24, 2.28)   0.54 (0.35, 0.84) 0.62 (0.39, 0.97) 
  Overweight and obese  5.27 (2.70, 10.28) 5.18 (2.58, 10.38)   1.94 (1.31, 2.86) 2.15 (1.41, 3.28) 
CI, Confidence interval.  
Hypertension: mean SBP ≥ 140 mmHg and/or mean DBP ≥ 90 mmHg and/or on anti-hypertensive drugs.  
Prehypertension: mean SBP between 120-139 mmHg and/or mean DBP between 80-89 mmHg. 
† Adjusted for sex, age, residence location, behavioral risk factors and BMI.  
‡ Behavioral risk factors include smoking, heavy alcohol consumption, less than 5 servings of fruit and vegetable consumption 
and low physical activity. 
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Table 4-5. Association between high and borderline-high cholesterolemia and HIV, STEPS, Cambodia, 2016 and 2019/2020. 
Predictors  
High cholesterolemia   Borderline-high cholesterolemia 
Crude OR 
(95% CI) 
Adjusted OR† 
(95% CI)   
Crude OR 
(95% CI) 
Adjusted OR† 
(95% CI) 
HIV+ (ref. young general population) 2.04 (1.37, 3.02) 7.95 (3.98, 15.87)   0.52 (0.34, 0.81) 0.98 (0.45, 2.15) 
Female (ref. male) 2.52 (1.65, 3.83) 5.10 (3.02, 8.60)   3.43 (2.20, 5.35) 3.59 (2.09, 6.14) 
Age  1.01 (0.95, 1.07) 1.05 (0.97, 1.12)   1.11 (1.04, 1.19) 1.09 (1.01, 1.16) 
Current address in Phnom Penh  1.53 (1.03, 2.26) 0.78 (0.43, 1.42)   0.64 (0.41, 1.01) 1.29 (0.61, 2.71) 
  (ref. in provinces)           
2 or more behavioral risk factors‡ 1.12 (0.68, 1.86) 1.38 (0.78, 2.45)   0.42 (0.21, 0.84) 0.72 (0.35, 1.49) 
BMI (ref. normal weight)           
  Underweight  0.88 (0.52, 1.49) 0.69 (0.39, 1.21)   0.36 (0.19, 0.68) 0.32 (0.16, 0.62) 
  Overweight and obese  1.10 (0.65, 1.87) 1.32 (0.75, 2.33)   1.24 (0.75, 2.20) 1.03 (0.61, 1.72) 
CI, Confidence interval.  
High cholesterolemia: total cholesterol between ≥ 240 g/dL and/or on cholesterol lowering drugs.  
Borderline-high cholesterolemia: total cholesterol between 200-239 g/dL. 
† Adjusted for sex, age, residence location, behavioral risk factors and BMI.  
‡ Behavioral risk factors include smoking, heavy alcohol consumption, less than 5 servings of fruit and vegetable consumption 
and low physical activity.  
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Figure 4-1. Plasma glucose levels among (fasting) study participants, stratified by BMI. 
 
 
 
 
  
Figure 4-2. Plasma glucose levels among (fasting) study participants, stratified by sex. 
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Figure 4-4. Association between total cholesterol and HIV, stratified by BMI and sex. 
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Figure 4-3. Distribution of cholesterolemia status by HIV-specific factors. 
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Chapter 5. Public health significance  
 
In Cambodia, research on non-communicable diseases remain limited due to many 
competing priorities in the health sector, a common scenario among low-middle-income 
countries (LMICs) which are undergoing demographic and epidemiological transition. 
Estimating burden of NCDs and assessing their risk factors is an important first step to NCD 
prevention. For PLWH and the general population alike, this assessment helps inform health 
research priorities and provides valuable insights into planning research studies and future 
intervention strategies, such as lifestyle modification and medications.  
These three studies contribute as evidence from LMICs, where heavy burden of both 
communicable and non-communicable conditions often intersect, although the latter is rarely 
addressed in scientific research publication.  
My first and third studies showed that adult PLWH and YLWH were at particularly 
higher odds of diabetes and prediabetes than the general population and young general 
population, although the general population group presented higher prevalence of traditional risk 
factors, such as smoking and heavy drinking. In addition, YLWH (but not the adult PLWH) were 
at higher odds of high cholesterolemia than the young general population. Although these 
metabolic disorders are also known to be commonly associated with ART, we found contrasting 
results among older adult PLWH and YLWH.  
Our findings on diabetes and prediabetes justify establishing screening and/or 
interventional measures among this population as well as further investigations into our current 
antiretroviral treatment guideline. These measures pertain as well to cholesterolemia as the ART 
regimen guidelines might be different between older and younger generation of PLWH. 
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My second study brought attention to cardiovascular disease or CVD among the 
population in Cambodia. CVD risk assessment is an important tool and the first step to guide 
prevention efforts and clinical treatments because in resource-limited settings, prevention 
measures remain the best options. This is particularly true, in the case of CVD, in which the 
elimination of its major (traditional) risk factors can greatly reduce its risk. Although the odds of 
moderate-to-high 10-year CVD risk were similar among PLWH and the general population, it is 
important to regularly perform CVD risk stratification among this population due to the highly 
prevalent glucose disorders (prediabetes), even in a young age group. Moreover, this population 
is linked in care, making it easier to start behavioral and/or medical interventions should the risk 
stratification tool estimate them to be at high risk.  
All three of my studies have contributed in terms of scientific knowledge and helped 
inform health research priorities for both PLWH and YLWH in Cambodia. With more powerful 
ART drugs, our focus should now be extended beyond viral suppression. Setting up behavioral 
and medical interventions as well as reinforcing screening efforts for metabolic disorders 
commonly associated with ART should also be considered as important as viral suppression. 
There should also be further studies, designed specifically to look into the effects of each ART 
regimen, both by class and by their individual compounds.  
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